Evidence map›Paper›PMID 37620675›Full record

ArticleCancer chemotherapy and pharmacology2024

Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection.

Cléa Tardy, Alicja Puszkiel, Pascaline Boudou-Rouquette, Sixtine De Percin, Jérôme Alexandre, Marion Berge, Guillaume Ulmann, Benoit Blanchet, Rui Batista, Francois Goldwasser and 1 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Factors associated with medication adherence trajectory among patients treated with oral anticancer drugs: a multicentre cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Cléa TardyPharmacy Department, Cochin Hospital (AP-HP), CARPEM, Paris, France. clea.tardy@aphp.fr.ORCID 0009-0008-3727-946X
Alicja PuszkielBiologie du Médicament-Toxicologie, Cochin Hospital (AP-HP), Paris, France.
Pascaline Boudou-RouquetteOncology Department, Cochin Hospital (AP-HP), CARPEM, Paris, France.
Sixtine De PercinOncology Department, Cochin Hospital (AP-HP), CARPEM, Paris, France.
Jérôme AlexandreOncology Department, Cochin Hospital (AP-HP), CARPEM, Paris, France.
Marion BergePharmacy Department, Cochin Hospital (AP-HP), CARPEM, Paris, France.
Guillaume UlmannService de Biochimie, Cochin Hospital (AP-HP), Paris, France.
Benoit BlanchetBiologie du Médicament-Toxicologie, Cochin Hospital (AP-HP), Paris, France.
Rui BatistaPharmacy Department, Cochin Hospital (AP-HP), CARPEM, Paris, France.
Francois GoldwasserOncology Department, Cochin Hospital (AP-HP), CARPEM, Paris, France.
Audrey Thomas SchoemannPharmacy Department, Cochin Hospital (AP-HP), CARPEM, Paris, France.
Hôpital Cochin · FRCentre National de la Recherche Scientifique · FRDélégation Paris 5 · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePazopanib is approved in advanced renal cell carcinoma (RCC) and soft-tissue sarcoma at a flat-fixed dose despite a large pharmacokinetics interindividual variability and a narrow therapeutic index. To our knowledge, pazopanib exposure in patients with gastrointestinal resections (GIR) has not been described. This report focuses on feasibility of pharmacokinetics-guided dose escalation in these patients and clinical implications for their management.

methodA retrospective data collection was performed for three patients with GIR treated with pazopanib, including pazopanib plasma concentrations (high-performance liquid chromatography with UV detection) and treatment adherence (Girerd score). CASE PRESENTATION: First patient (55-year-old man, RCC, gastric bypass surgery) pazopanib C

conclusionOptimal pazopanib exposure cannot be achieved in patients with GIR, and thus, other therapeutic strategies should be encouraged. Pretherapeutic assessment seems crucial to evaluate factors as bariatric surgery that may impact pazopanib concentrations. Therapeutic drug monitoring could be helpful to optimize pazopanib response in these patients.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsPyrimidinesSarcomaSoft Tissue NeoplasmsSulfonamidesFemaleHumansIndazolesMaleMiddle AgedRetrospective StudiesIndazolespazopanibPyrimidinesSulfonamidesDose escalationGastrointestinal resectionsPazopanibTherapeutic drug monitoring

Identifiers

PMID37620675
OpenAlexW4386127071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.